Immunovant postpones trial readouts for its late-stage FcRn drug as it prioritizes another
Following a recently completed Type B meeting with the FDA, Immunovant is on track to initiate 4 to 5 potentially registrational studies for its lead asset IMVT-1402 in endocrinology, neurology, and...
What Makes Immunovant (IMVT) a New Buy Stock
Immunovant Awarded U.S. Patent for IMVT-1402
Immunovant plans to initiate 4-5 potentially registrational programs for IMVT-1402 over the next fiscal year Immunovant plans to initiate trials in 10 indications for IMVT-1402 over the next two...
NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today...
Immunovant’s drug for Graves’ disease showed a response rate that exceeded 50% in an initial cohort of patients in an ongoing 24-week Phase II clinical trial, the company announced late Thursday afternoon.
Immunovant has advanced its mission to claim an unoccupied area of the competitive anti-FcRn space, reporting phase 2 data that support its attempt to be the first to market in Graves’ disease.
NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today...
Results from the 600 mg MAD cohort for IMVT-1402 similar to previously disclosed results from the 300 mg MAD cohort for IMVT-1402IMVT-1402 was observed to deliver dose dependent and deep IgG...